Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2CNS 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 5Adenocarcinoma of Lung 5Lymphoma, Large-Cell, Anaplastic 2Hematologic Neoplasms 2Granuloma, Plasma Cell 2Rhabdomyosarcoma 1Noonan Syndrome 6 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, B-Cell 1Glioblastoma 1Brain Neoplasms 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1

Interventions

ceritinib 2pazopanib 1Radiotherapy 1Radiation 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Granuloma, Plasma Cell × ceritinib × Clear all
NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed
83 enrolled 30 charts
CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡